JP Morgan Adds St Jude Medical To Focus List

JP Morgan has added St Jude Medical STJ to the JP Morgan Focus List, stating "Yesterday's 2Q results and the lowering of 2H guidance was in our view a clearing event for the stock. The US ICD market has yet to stabilize, but this is now well reflected in management guidance and for the first time in months the Street can look past CRM and start to focus on the new product and new market driven growth acceleration story on tap for 2012. We see several catalysts into year-end and would be buyers of the stock at current levels."